U.S., Oct. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07215637) titled 'Phase Ia/Ib Study of CKD-512 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Solid Tumors' on Sept. 24.
Brief Summary: The purpose of this first-in-human (FiH) study is to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of CKD-512 given alone and in combination with pembrolizumab in subjects with advanced or metastatic solid tumors who have failed all standard available therapy.
Study Start Date: Oct., 2025
Study Type: INTERVENTIONAL
Condition:
Advanced Solid Tumors
Metastatic Solid Tumors
Intervention:
DRUG: CKD-512
Orally administere...